The Same, but Different: Shared Hallmarks and Divergent Drivers in Adult, Pediatric and Canine Glioma
Current Oncology · 2026
DOI: 10.3390/curroncol33100592 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2026. Verfasst von R Timothy Bentley und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Small Animal Clinical Science, University of Liverpool, Liverpool CH64 7TE, UK. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Dog Diseases. Die Arbeit nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS, Purdue University Institute for Cancer Research.
Abstract (Originalsprache)
Malignant gliomas are the most common primary brain tumors, with dismal outcomes. Pet dogs have been proposed as a valuable model for studying gliomas. Here, we compare spontaneously occurring gliomas from adult and pediatric human and canine patients, focusing on the tumor microenvironment (TME) and the canonical pathways of human glioma dysregulation (RTK/RAS/PI(3)K, p53 and Rb). Transcriptomic, genomic, and methylation data from adult, pediatric, and canine samples were evaluated. Across cohorts, aberrant signaling in the three canonical pathways correlated with increasing tumor grade. Canine high-grade glioma (HGG) showed extensive pathway dysregulation, especially when incorporating differentially expressed genes such as TP53. PDGFRA was a key driver of glioma in purebred brachycephalic (“short-skulled”) dogs. IDH1 mutations and hypermethylation were concentrated in adult tumors. Both species exhibited increased neutrophils, M2 macrophages, and regulatory T cells, coupled with depletion of key antitumor effectors. PD-1 and PD-L1 immune checkpoint biology was similarly preserved. Canine glioma seems to occupy a “middle ground” between pediatric and adult. Methylation patterns mirrored pediatric glioma, yet immune infiltration and pathway activation resembled adult HGG. Complex heterogeneity between patients was a major similarity between species. Despite different driver mutations, dogs and humans converge on a similar malignant, immune-suppressed TME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Small Animal Clinical Science, University of Liverpool, Liverpool CH64 7TE, UK.
- Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN 47906, USA.
- Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN 47906, USA.
- Department of Statistics, Purdue University, West Lafayette, IN 47906, USA.
- Department of Epidemiology and Biostatistics, UC Irvine, Irvine, CA 92697, USA.
- Cancer Data Science Initiatives, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
ORCID-Profile: R Timothy Bentley, Sagar M Utturkar, Harish Kothandaraman, Danni Liu, Matthew Beyers, Nadia A Lanman
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- Purdue University Institute for Cancer Research
- Walther Cancer Foundation
- National Cancer Institute
- University of California
Zitieren
APA
Bentley, R. T., Utturkar, S. M., Kothandaraman, H., Dhawan, D., Liu, D., Beyers, M., Zhang, M., Knapp, D. W., & Lanman, N. A. (2026). The Same, but Different: Shared Hallmarks and Divergent Drivers in Adult, Pediatric and Canine Glioma. Current Oncology. https://doi.org/10.3390/curroncol33100592
Vancouver
Bentley RT, Utturkar SM, Kothandaraman H, Dhawan D, Liu D, Beyers M, et al. The Same, but Different: Shared Hallmarks and Divergent Drivers in Adult, Pediatric and Canine Glioma. Current Oncology. 2026. doi:10.3390/curroncol33100592
BibTeX
@article{Bentley2026,
author = {Bentley, R Timothy and Utturkar, Sagar M and Kothandaraman, Harish and Dhawan, Deepika and Liu, Danni and Beyers, Matthew and Zhang, Min and Knapp, Deborah W and Lanman, Nadia A},
title = {The Same, but Different: Shared Hallmarks and Divergent Drivers in Adult, Pediatric and Canine Glioma},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33100592}
}
EUVIMED